Publication Topic

Nordyke RJ, Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health; doi: 10.1016/j.jval.2025.08.011. Online ahead of print Sept. 1, 2025. PMID: 40902797.

Patterson JA, Motyka J, Salih R, Nordyke RJ, O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6. PMID: 39369117.

Wagner TD, Westrich KD, Nordyke RJ, Campbell JD. 2024. Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: Contextualizing drug spending changes. J Med Econ 27(1):1537-1541; doi: 10.1080/13696998.2024.2428109. PMID: 39626873.

Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. 2012. U.S. payer perspectives on evidence for formulary decision-making. J Oncol Pract 8(3 Suppl):22s-27s; doi: 10.1200/JOP.2011.000526. PMID: 22942820.